Flow cytometric evaluation of cancer stem cell markers in HepG2 cells following sorafenib treatment

Basit Öğe Kaydı
dc.authorid0000-0002-4605-1167en_US
dc.authorid0000-0001-5114-8660en_US
dc.authorid0000-0002-3060-1507en_US
dc.authorid0000-0003-0674-090Xen_US
dc.authorid0000-0002-4474-7371en_US
dc.contributor.authorDönmez Çakıl, Yaprak
dc.contributor.authorSitar, Mustafa Erinç
dc.contributor.authorÖzünal, Zeynep Güneş
dc.contributor.authorGökçeoğlu Kayalı, Damla
dc.contributor.authorAktaş, Ranan Gülhan
dc.date.accessioned2024-07-12T21:04:16Z
dc.date.available2024-07-12T21:04:16Z
dc.date.issued2021en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractObjectives: Liver cancer is a leading cause of mortality. Sorafenib resistance and cancer stem cells (CSCs) are among the factors that contribute to a poor prognosis. Different drugs enrich different CSC populations with a variety of CSC markers. This study investigated the expression of CSC markers in HepG2 cells in response to low doses of sorafenib using flow cytometry. Methods: The cytotoxicity of sorafenib was determined using a cell counting kit-8 assay. The expressions of the CSC markers CD44, CD90, and CD133 were measured with flow cytometry after treatment with sorafenib for 72 hours. Results: Sofranib inhibited cell proliferation in a dose-dependent manner. Low-dose sorafenib treatment increased CD44 expression; however, there was a decrease in the expression of CD133. An increasing trend was also seen in CD90 expression, but the difference was not significant. Conclusion: The results indicate that CSC expression varied according to the sorafenib dose administered, which supports the role of CSCs as novel pharmacological targets and highlights the importance of their characterization and the ability to identify them.en_US
dc.identifier.citationDönmez Çakıl, Y., Sitar, M.E., Özünal, Z.G., Gökçeoğlu Kayalı, D. ve Aktaş, R.G. (2021). Flow cytometric evaluation of cancer stem cell markers in HepG2 cells following sorafenib treatment. International Journal Of Medical Biochemistry, Association of Clinical Biochemistry Specialists. 4(3), s. 200-204en_US
dc.identifier.doi10.14744/ijmb.2021.63935
dc.identifier.endpage204en_US
dc.identifier.issn2618-642X
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85164147022en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage200en_US
dc.identifier.trdizinid487373en_US
dc.identifier.urihttps://jag.journalagent.com/ijmb/pdfs/IJMB-63935-ORIGINAL_INVESTIGATION-SITAR.pdf
dc.identifier.urihttps://doi.prg/10.14744/ijmb.2021.63935
dc.identifier.urihttps://hdl.handle.net/20.500.12415/3770
dc.identifier.volume4en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.institutionauthorDönmez Çakıl, Yaprak
dc.institutionauthorSitar, Mustafa Erinç
dc.institutionauthorÖzünal, Zeynep Güneş
dc.institutionauthorGökçeoğlu Kayalı, Damla
dc.institutionauthorAktaş, Ranan Gülhan
dc.language.isoenen_US
dc.publisherAssociation of Clinical Biochemistry Specialistsen_US
dc.relation.ispartofInternational Journal Of Medical Biochemistryen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY01664
dc.subjectBiomarkeren_US
dc.subjectcancer stem cellsen_US
dc.subjectflow cytometryen_US
dc.subjecthepatocellular canceren_US
dc.subjectsorafeniben_US
dc.titleFlow cytometric evaluation of cancer stem cell markers in HepG2 cells following sorafenib treatmenten_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu